Two U.S. Food and Drug Administration (FDA)–approved mRNA vaccines for COVID-19 have saved millions of lives. These vaccines were developed with NIH support and research on a protein found on SARS-CoV-2, the virus that causes COVID-19. Clinical trials for the COVID-19 vaccines in people were established in what seemed like record time. But in reality, more than 50 years of public and private laboratory research laid the groundwork for the rapid development of these life-saving vaccines.
Studies of viruses, including other coronaviruses, human immunodeficiency virus (HIV), and respiratory syncytial virus (RSV); advances in general vaccine technology; and the breakthrough in using fatty, oil-like particles called lipid nanoparticles to deliver vaccines to cells were just some of the efforts that made the mRNA COVID-19 vaccines possible. For decades, NIH has supported the research that led to these vaccines — and this timeline provides some of the best examples.
Knowledge of mRNA and Viruses Grows
1961 to 1990
Scientists discover mRNA and how it can either activate or block protein production in cells. They start to study its use in medicine. Source 1, Source 2
1987
NIH launches the HIV/AIDS Clinical Trials Networks. The flexibility and rapid-response design of these networks acts as a framework for future responses to other viruses and infectious diseases, including SARS-CoV-2.
Early 1990s
Congress and NIH set aside 10% of NIH’s yearly budget for HIV/AIDS research, funding that continues through 2016 and supports discoveries about the virus, that help in understanding other viruses.
Studies of Other Viruses and mRNA Breakthroughs Advance Vaccine Science
Early 2000s
NIH scientists lay the foundation for structure-based vaccine design by finding that the structure of a protein on the surface of the human immunodeficiency virus allows it to enter human cells. Source
2005
A laboratory breakthrough shows that modified mRNA can safely deliver instructions to cells without over-activating the body’s immune system. Source
2005 to 2016
Scientists investigate the use of lipids as envelopes to deliver information to the cells of the body. These studies eventually lead to the creation of the lipid nanoparticles used as the outer envelopes for mRNA vaccines against COVID-19. Source
2013
NIH scientists discover the structure of virus proteins that let viruses invade cells. This finding leads scientists to create the first stabilized proteins for use in vaccines that provoke a strong immune response to viruses such as RSV, a major cause of severe disease in infants and older adults. Source
2014 to 2018
NIH’s response to the Ebola epidemic in the Democratic Republic of Congo helps establish pathways to streamline and speed up regulatory review and emergency use of investigational treatments during critical disease outbreaks. Source
2016
By stabilizing the coronavirus “spike protein” that lets HKU1, a form of the common cold, invade cells, NIH scientists are able to better understand coronavirus immunity. Source
2016
Scientists from NIH and Moderna begin to collaborate on a general vaccine design that uses viral mRNA. This design can be quickly adapted to protect people from emerging viruses such as Nipah virus and the Middle East respiratory syndrome (MERS) coronavirus. Source
2017
NIH scientists stabilize the spike protein that MERS uses to invade cells, allowing researchers to better understand how to build an effective vaccine against coronaviruses. Source
2017
Through study of a Zika virus DNA-based vaccine, NIH scientists discover that gene-based vaccines, such as those using mRNA, are safe and effective, paving the way for development of mRNA vaccines. Source
2019
NIH and Moderna scientists plan for Phase 1 clinical trials to test the safety of mRNA vaccines for Nipah virus; the trials began in 2022. Source 1, Source 2
COVID-19 Pandemic Begins
December 31, 2019
The first cluster of people sick with what is now called COVID-19 is reported in Wuhan, China. Global response begins almost right away. The U.S. government comes together with private, non-governmental, and academic organizations to begin work on COVID-19 vaccines. Source
January 2020
Chinese scientists share the first genetic sequence of SARS-CoV-2 with the NIH database GenBank. Scientists from NIH and Moderna quickly pivot from studies of other viral vaccines to focus on a vaccine candidate for COVID-19, mRNA-1273, to respond to the outbreak. Source 1, Source 2
March 11, 2020
The World Health Organization (WHO) declares COVID-19 a pandemic. Source
March 16, 2020
NIH clinical trials for the Moderna mRNA vaccine begin. Source
April 17, 2020
NIH launches Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a first-of-its-kind public-private partnership for developing COVID-19 treatments and vaccines.
May 15, 2020
Operation Warp Speed launches to coordinate federal government efforts that speed up the approval and production of reliable COVID-19 diagnostics, vaccines, and treatments. Source 1, Source 2
July 8, 2020
NIH launches the COVID-19 Prevention Network (CoVPN), which uses the existing structure of NIH clinical trial networks to support trials of COVID-19 vaccines and other prevention tools. Source
November 16, 2020
A large-scale Phase 3 clinical trial of the Moderna mRNA vaccine shows promising interim results. Source
mRNA Vaccines for COVID-19 Ready for People
December 11, 2020
The FDA grants an emergency use authorization (EUA) to the Pfizer-BioNTech mRNA vaccine for people age 16 and older. Source
December 18, 2020
The FDA grants an EUA to the Moderna mRNA vaccine for people age 18 and older. Source
August 23, 2021
The FDA grants full approval to the Pfizer-BioNTech mRNA vaccine for people age 16 and older. Source
October 29, 2021
The FDA grants an EUA to the Pfizer-BioNTech mRNA vaccine for children age 5 to 11. Source
January 31, 2022
The FDA grants full approval to the Moderna mRNA vaccine for people age 18 and older. Source
March 14, 2022
NIH launches Phase 1 clinical trials for three mRNA HIV vaccines. These vaccines apply lessons learned from the development of mRNA vaccines for COVID-19. Source
March 2022
Data show that the U.S. COVID-19 vaccination program is estimated to have prevented 2 million deaths, 17 million hospitalizations, and 66 million infections through March 2022. Vaccination is also estimated to have saved nearly $900 billion in health care costs. Source
June 17, 2022
The FDA grants an EUA to the Pfizer-BioNTech and Moderna mRNA vaccines for children age 6 months or older. Source
July 11, 2022
NIH launches a Phase 1 clinical trial for an mRNA Nipah virus vaccine. Source
August 31, 2022
The FDA grants an EUA of the Moderna and Pfizer-BioNTech COVID-19 vaccines to authorize bivalent formulations for use as a booster dose. These updated boosters contain mRNA components for both the original strain of SARS-CoV-2 and its Omicron variant. Source
December 8, 2022
The FDA grants an EUA to the Pfizer-BioNTech and Moderna bivalent COVID-19 vaccines for children age 6 months or older. Source
